ProStraken Abstral Approved to Manage Cancer Pain

10 January 2011 (Last Updated January 10th, 2011 18:30)

The US Food and Drug Administration (FDA) has approved ProStraken Abstral (fentanyl) transmucosal tablets for the management of breakthrough pain in adults with cancer. Fentanyl immediate-release transmucosal medications are administered on the soft surfaces of the mouth, the nasal pas

The US Food and Drug Administration (FDA) has approved ProStraken Abstral (fentanyl) transmucosal tablets for the management of breakthrough pain in adults with cancer.

Fentanyl immediate-release transmucosal medications are administered on the soft surfaces of the mouth, the nasal passages or the throat, where they dissolve and are absorbed.

Abstral is indicated for use by cancer patients aged 18 years and older, who already use opioid medication round the clock, and who need and are able to safely use high doses of an opioid medication.

Abstral is available only through a Risk Evaluation and Mitigation Strategy (REMS) programme, which is designed to minimise the risk of misuse, abuse, addiction and overdose.